en · de · es · pt
epitalon-notes.peptides8425.com › Data › Origin And Telomerase Research Claims — Explained

Origin And Telomerase Research Claims — Explained

By Editorial Desk · published 2025-10-02 · last reviewed 2025-11-07 · Data

If you have been reading about Khavinson and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Last reviewed on 2025-11-07. Where a claim depends on a specific study, the study is described rather than over-claimed.

Origin and Telomerase Research Claims

Epitalon emerged from research conducted in Saint Petersburg by Vladimir Khavinson and colleagues, who studied short peptides as potential regulators of aging. The work built on epithalamin, a pineal gland extract reported to influence neuroendocrine function. Epitalon was designed as a synthetic counterpart with a defined sequence, allowing reproducible experiments that extracts could not support. Early publications described effects on melatonin rhythms and lifespan in animal models. These findings circulated mainly in Russian-language journals during the 1990s, which limited their visibility among English-speaking researchers.

The most widely cited claim is that epitalon activates telomerase and thereby extends telomere length. Supporting evidence comes largely from cultured human cells, where treatment was associated with increased telomerase activity and delayed replicative senescence. Telomerase activation is a biologically consequential effect, since the enzyme is largely silenced in most somatic cells. However, the route by which a short peptide would reach and act on the enzyme's regulatory machinery has not been established. Independent replication in human trials is scarce, so the link between cell-culture observations and whole-body aging remains an open question.

Epitalon Background and Nomenclature

The compound is generally presented as a synthetic fragment of epithalamin, a pineal gland extract investigated in the former Soviet Union from the 1970s onward. Vladimir Khavinson and colleagues in Saint Petersburg developed short peptides modelled on such extracts, and epitalon became the most widely cited of those sequences. Most primary reports appeared in Russian-language journals or in proceedings with limited international circulation. Independent replication in laboratories outside that network remains sparse, and much repeated secondary material traces back to a small number of originating groups.

Laboratory work has examined effects on telomerase activity in cultured cells, on melatonin rhythms in animals, and on markers of oxidative stress. Some experiments report measurable changes while others show none, and the reported findings rest largely on small studies. The absence of large independent trials means the generality of these results is unresolved rather than settled. Review articles occasionally apply the label geroprotector, a term that reflects a research hypothesis about ageing rather than an established clinical finding.

Epitalon is the common name for a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, usually abbreviated AEDG. All four residues are proteinogenic amino acids, and the free peptide has a calculated mass near 390 grams per mole. Because the chain is short and carries no modifications, it is assembled readily by solid-phase synthesis and is distributed mainly as a freeze-dried solid for laboratory work. Catalogue listings use the spellings epitalon, epithalone, and simply AEDG, and the three refer to the same sequence.

Epitalon at a glance

PropertyValueNotes
Peptide sequenceAla-Glu-Asp-GlySingle-letter form AEDG
Compound classSynthetic tetrapeptideNot a natural free peptide
Research originRussian gerontology institutesDeveloped during the 1990s
Main research claimTelomerase activationEvidence mainly from cultured cells
Regulatory statusNot an approved drugHandled as a research material

Epitalon in Research Literature and Handling

Analytical characterization of epitalon relies on standard peptide methods. Reverse-phase high-performance liquid chromatography is used to assess purity, and mass spectrometry confirms identity by checking the observed mass against the expected value near 390 daltons. Amino acid analysis can verify composition. Because the peptide is short and hydrophilic, it elutes early on many reverse-phase columns, so method development often requires ion-pairing reagents to achieve adequate retention and resolution from related impurities.

Storage and handling follow conventional peptide practice. Lyophilized epitalon is typically kept refrigerated or frozen, protected from moisture and light, and allowed to equilibrate to room temperature before opening to avoid condensation. Once dissolved, aqueous solutions are usually stored cold and used within a short period, since dilute peptide solutions can support microbial growth and may slowly degrade. The absence of cysteine and methionine reduces, but does not eliminate, oxidation concerns during long-term storage.

Regulatory status varies by country and is not harmonized. Epitalon is not an approved drug in major Western jurisdictions. In some countries it is sold as a research chemical, and in others it has appeared in products marketed for other categories. This inconsistent status means that purity, labeling accuracy, and documentation differ widely between suppliers, and verification of identity and purity through independent analysis is the usual way buyers assess a given lot.

Related pages on this site

Epitalon Background And Identification

Epitalon is a synthetic tetrapeptide with the residue sequence alanine-glutamate-aspartate-glycine, commonly abbreviated AEDG. Its monoisotopic mass is approximately 390.35 daltons, and it is usually supplied as a lyophilised trifluoroacetate or acetate salt. The compound was derived from a pineal gland extract called epithalamin, a heterogeneous preparation investigated in the former Soviet Union. Researchers associated with the Saint Petersburg Institute of Bioregulation and Gerontology described the tetrapeptide as a constituent fragment of that extract. Commercial material is offered as a laboratory reagent rather than as a finished pharmaceutical product.

Literature searches for this compound must account for several spelling variants. Indexing databases contain epitalon, epithalon, epithalone, and AEDG, and relevant records are scattered across Russian-language and English-language journals that do not consistently cross-cite. Early publications describe the parent extract as a mixture of many peptides, whereas later work addresses the single synthetic tetrapeptide. That shift in nomenclature complicates comparison between studies, because extract data and tetrapeptide data are sometimes cited interchangeably. A search strategy omitting the alternate spellings will return an incomplete set of references.

Reported biological findings come mainly from cell culture and rodent experiments. Those studies describe changes in telomerase catalytic subunit expression, melatonin rhythm amplitude, and antioxidant enzyme activity after peptide exposure. Human data are sparse and consist of small trials with limited blinding and inconsistent endpoints. The proposed mechanisms remain hypotheses rather than established facts, and there is no consensus on whether effects observed in animals carry over to people. Independent replication outside the original research groups is limited, which is a recognised gap in the published literature.

Analytical Methods and Storage

Verification of research-grade material involves comparing a supplier chromatogram against an in-house reference, checking the observed mass against the calculated value, and where possible confirming residue order by tandem mass spectrometry or enzymatic peptide mapping. Purity claims should be read alongside the method used to obtain them, because detection wavelength and integration settings alter the result. Batch-specific data, rather than a generic grade statement, is the informative part of a certificate.

Identity and purity of epitalon samples are normally established by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres, combined with mass spectrometry. The mass spectrum confirms the expected molecular ion and can reveal truncated or oxidised by-products. Amino acid analysis after acid hydrolysis verifies that the four residues are present in the expected ratio. Certificates typically report a purity figure taken from chromatographic peak area, expressed as a percentage of total integrated signal.

Lyophilised epitalon is generally held at minus twenty degrees Celsius in a sealed container kept dry and dark. Cooler conditions are sometimes recommended for long-term archives. The solid takes up moisture readily enough that repeated opening of a vial introduces water, so dividing a batch into smaller portions before storage lowers degradation risk. Aqueous solutions are less durable than the dry powder and are usually prepared shortly before use, then kept cold and shielded from light to slow hydrolysis and oxidation.

Background and Proposed Mechanism

The most frequently cited proposed action is induction of telomerase, the enzyme that adds repeat sequences to chromosome ends. Cell-culture work from the originating group reported higher telomerase reverse transcriptase expression and measurable telomere elongation in human somatic cells after exposure. How a four-residue peptide would reach nuclear gene regulation is not established, and no cell-surface receptor or uptake route has been identified. Additional reports describe changes in melatonin secretion, antioxidant enzyme activity and lipid peroxidation in aged animals, but these findings remain mechanistically unconnected to the telomerase observation.

Published evidence comes mainly from Russian-language journals and from a single research group, with small sample sizes and limited independent replication. A few laboratories outside that group have examined related peptides and reported weaker or absent telomerase effects, so the central claim is best described as contested rather than settled. Rodent studies report modest changes in some ageing markers and in survival, but designs vary and control conditions are often sparse. No large randomised trial in humans has been published, and long-term safety data in healthy populations are correspondingly thin.

Supporting material

== Epidemiology == Anorexia is estimated to occur in 0.9–4.3% of women and 0.2–0.3% of men in Western countries at some point in their life. About 0.4% of young females are affected in a given year and it is estimated to occur three to ten times less commonly in males. The cause of this disparity is not well-established but is thought to be linked to both biological and socio-cultural factors. Rates in most of the developing world are unclear. Often it begins during the teen years or young adulthood. Medical students are a high risk group, with an overall estimated prevalence of 10.4% globally. The lifetime rate of atypical anorexia nervosa, a form of ED-NOS in which the person loses a significant amount of weight and is at risk for serious medical complications despite having a higher body-mass index, is much higher, at 5–12%. Additionally, a UCSF study showed severity of illness is independent of current BMI, and "patients with large, rapid, or long-duration of weight loss were more severely ill regardless of their current weight." While anorexia became more commonly diagnosed during the 20th century it is unclear if this was due to an increase in its frequency or simply better diagnosis. Most studies show that since at least 1970 the incidence of AN in adult women is fairly constant, while there is some indication that the incidence may have been increasing for girls aged between 14 and 20.

So, in Pubblico Ministero v Ratti because the Italian government had failed to implement a Directive 73/173/EEC on packaging and labelling solvents by the deadline, it was estopped from enforcing a conflicting national law from 1963 against Mr Ratti's solvent and varnish business. A member state could "not rely, as against individuals, on its own failure to perform the obligations which the Directive entails". Second, a citizen or company can also invoke a Directive as a defence in a dispute with another citizen or company (not just a public authority) which is attempting to enforce a national law that conflicts with a Directive. So, in CIA Security v Signalson and Securitel the Court of Justice held that a business called CIA Security could defend itself from allegations by competitors that it had not complied with a Belgian decree from 1991 about alarm systems, on the basis that it had not been notified to the commission as a Directive required. Third, if a Directive gives expression to a "general principle" of EU law, it can be invoked between private non-state parties before its deadline for implementation. This follows from Kücükdeveci v Swedex GmbH & Co KG where the German Civil Code §622 stated that the years people worked under the age of 25 would not count towards the increasing statutory notice before dismissal. Ms Kücükdeveci worked for 10 years, from age 18 to 28, for Swedex GmbH & Co KG before her dismissal. She claimed that the law not counting her years under age 25 was unlawful age discrimination under the Employment Equality Framework Directive.

Many kinds of isomerism exist in coordination complexes. Just as in organic chemistry, isomers are of two types: diastereomers (also called diastereoisomers) and enantiomers. Enantiomers are non-superimposable mirror images. Diastereomers are all other types of isomers.

The N‑terminal peptide is cleaved (split) from the zymogen enzyme precursor by another enzyme to release an active enzyme. The binding site of inhibitors on enzymes is most commonly the same site that binds the substrate of the enzyme. These active site inhibitors are known as orthosteric ("regular" orientation) inhibitors. The mechanism of orthosteric inhibition is simply to prevent substrate binding to the enzyme through direct competition which in turn prevents the enzyme from catalysing the conversion of substrates into products. Alternatively, the inhibitor can bind to a site remote from the enzyme active site. These are known as allosteric ("alternative" orientation) inhibitors. The mechanisms of allosteric inhibition are varied and include changing the conformation (shape) of the enzyme such that it can no longer bind substrate (kinetically indistinguishable from competitive orthosteric inhibition) or alternatively stabilise binding of substrate to the enzyme but lock the enzyme in a conformation which is no longer catalytically active.

Sources: en.wikipedia.org

Notes from published material

It is a measurement of the contribution of a genotype to the next generation where a value of 1 would be completely selected against and make no contribution and 0 is not selected against at all. This definition of neutral mutation has been criticized due to the fact that very large effective population sizes can make mutations with small selection coefficients appear non neutral. Additionally, mutations with high selection coefficients can appear neutral in very small populations. The testable hypothesis of Kimura and others showed that polymorphism within species are approximately that which would be expected in a neutral evolutionary model. For many molecular biology approaches, as opposed to mathematical genetics, neutral mutations are generally assumed to be those mutations that cause no appreciable effect on gene function. This simplification eliminates the effect of minor allelic differences in fitness and avoids problems when a selection has only a minor effect. Early convincing evidence of this definition of neutral mutation was shown through the lower mutational rates in functionally important parts of genes such as cytochrome c versus less important parts and the functionally interchangeable nature of mammalian cytochrome c in in-vitro studies. Nonfunctional pseudogenes provide more evidence for the role of neutral mutations in evolution. The rates of mutation in mammalian globin pseudogenes has been shown to be much higher than rates in functional genes.

The final withdrawal of the Mustang from USAF placed hundreds of P-51s onto the civilian market. The rights to the Mustang design were purchased from North American by the Cavalier Aircraft Corporation, which attempted to market the surplus Mustang aircraft in the US and overseas. In 1967 and again in 1972, the USAF procured batches of remanufactured Mustangs from Cavalier, most of them destined for air forces in South America and Asia that were participating in the Military Assistance Program (MAP). These aircraft were remanufactured from existing original F-51D airframes fitted with new V-1650-7 engines, a new radio, tall F-51H-type vertical tails, and a stronger wing that could carry six 12.7 mm (0.50 in) machine guns and a total of eight underwing hardpoints. Two 1,000-pound (450 kg) bombs and six 127 mm (5 in) rockets could be carried. They all had an original F-51D-type canopy but carried a second seat for an observer behind the pilot. One additional Mustang was a two-seat, dual-control TF-51D (67-14866) with an enlarged canopy and only four wing guns. Although these remanufactured Mustangs were intended for sale to South American and Asian nations through the MAP, they were delivered to the USAF with full USAF markings. They were, however, allocated new serial numbers (67-14862/14866, 67-22579/22582 and 72-1526/1541). The last US military use of the F-51 was in 1968 when the US Army employed a vintage F-51D (44-72990) as a chase aircraft for the Lockheed YAH-56 Cheyenne armed helicopter project.

An important example of catch bonds is their role in leukocyte extravasation. During this process, leukocytes move through the circulatory system to sites of infection, and in doing so they 'roll' and bind to selectin molecules on the vessel wall. While able to float freely in the blood under normal circumstances, shear stress induced by inflammation causes leukocytes to attach to the endothelial vessel wall and begin rolling rather than floating downstream. This "shear-threshold phenomenon" was initially characterized in 1996 by Finger et al. who showed that leukocyte binding and rolling through L-selectin is only maintained when a critical shear-threshold is applied to the system. Multiple sources of evidence have shown that catch bonds are responsible for the tether and roll mechanism that allows this critical process to occur. Catch bonds allow increasing force to convert short-lived tethers into stronger, longer-lived binding interactions, thus decreasing the rolling velocity and increasing the regularity of rolling steps. However, this mechanism only works at an optimal force. As shear force increases past this force, bonds revert to slip bonds, creating an increase in velocity and irregularity of rolling.

Sources: en.wikipedia.org

Background from the literature

He also receives further instruction from Morpheus on subjects such as "freeing his mind" from the restrictions of the Matrix, essentially overcoming the physics engine the Matrix operates on. He is also informed of the existence of its agents, programs designed by the machines to maintain order and dominance over the human race, created with abilities such as dodging bullets, running at high speeds, jumping great distances, and physically possessing people in the Matrix. If killed, they simply find a new host to overcome. After several days aboard Morpheus' hovercraft, the Nebuchadnezzar, Neo is taken to meet the Oracle, who has the power of foresight within the simulated world. She tells him that he has the "gift", but appeared to be waiting for something, and that in his present life he is not the One. The Oracle warns him that a situation will arise when he will have to choose between saving his own life or that of Morpheus. Returning from the Oracle to a landline phone, which serves as the exit for "red pills" to leave the Matrix, the crew of Morpheus's ship is betrayed by Cypher, a "red pill" who is willing to give the agents Morpheus in exchange for the promise of being mentally erased and reconnected permanently to the Matrix as an escape from the real world's bleakness. In the Matrix, SWAT troops kill Mouse. Cypher jacks out and grabs a real-world lightning gun, injuring Tank and killing Dozer. He kills Apoc and Switch, who remain jacked in, by prematurely terminating their connections. In the Matrix, Smith defeats and captures Morpheus.

In Ethiopia and Zambia, elaborate scarification is often done on women at puberty, used to denote a willingness to be a mother. The markings show that she can stand the pain of childbirth, as well as being an indication of her emotional maturity.

=== ISCEA Expansion into Europe, the Middle East and Africa === Since 2010 ISCEA has been organizing Supply Chain Management Summits and certification workshops in UAE and Saudi Arabia. In 2014 the French Supply Chain Management Association (FAPICS), introduced to France ISCEA's CDDP (Certified Demand Driven Planner) certification program; and in 2016 it introduced CSCA (Certified Supply Chain Analyst). ISCEA's SCTECH 2019 was held in France in parallel to FAPICS Conference. In 2020, FAPICS changed its name to l'Association francophone de Supply Chain Management (AfrSCM), maintaining the collaboration and promoting ISCEA's certifications to schools like IAE Paris - Sorbonne Business School, and its member companies. ISCEA collaborated in 2019 with Africa Resource Centre (ARC) awarding future leaders of Nigeria with Certified Supply Chain Analyst (CSCA) and Certified HealthCare Supply Chain Analyst (CHSCA) scholarships worth US$550,000. ARC is an independent supply chain advisor to Ministries of Health of African Countries, aimed to improve availability of medicine and health in Africa. In 2021 ISCEA entered into a partnership with Supply Chain Economy-Management (SCE-Management). The focus of this partnership will be strengthening supply chain systems through both capacity building and certification in Benin and French-speaking Africa. In 2025, the American University in Cairo - Onsi Sawiris School of Business Executive Education (ExecEd) secured ISCEA accreditation for its Supply Chain Management Professional Certificate.

=== Additive for cosmetics === The juice can be used in skin creams due to its high polyphenol, vitamin and protein content. Hemp salt unfolds its soothing effect on neurodermatitis as a bath additive. Hemp juice is now appearing as an inactive ingredient in many cosmetic products.

Sources: en.wikipedia.org

Frequently asked questions

Who developed epitalon?

Vladimir Khavinson and colleagues at research institutes in Saint Petersburg developed and studied the peptide. Their program examined short peptides as regulators of aging and neuroendocrine function. Epitalon was one of several compounds produced by that group.

Does epitalon lengthen telomeres in humans?

That question is not settled. Cell culture studies have reported increased telomerase activity after treatment, but comparable evidence from controlled human trials is lacking. Any claim about telomere lengthening in people should be treated as unproven.

Why is epitalon not an approved medicine?

It has not completed the large, controlled trials required for drug approval in major jurisdictions. Most human reports involve small samples and limited follow-up. As a result, it is sold as a research chemical rather than a licensed pharmaceutical product.

What is epitalon made of?

It is a four-amino-acid peptide with the sequence alanine-glutamate-aspartate-glycine. The chain is unmodified and contains only standard proteinogenic residues, which makes it straightforward to produce by solid-phase synthesis and to characterise by standard peptide methods.

Network